Brain Tumor Signs and Symptoms: Analysis of Primary Health Care Records from the UKCCS
Overview
Affiliations
Objective: To compare the frequency of brain tumor signs and symptoms in children with and without brain tumors.
Methods: This was a UK population-based retrospective analysis of primary care records. Participants were 195 children (1-14 years) newly diagnosed with brain tumors and 285 controls matched by age, gender, and region. Comparisons included total number of prediagnosis consultations, number with >or=1 symptom suggestive of a brain tumor, total number of symptoms, number of different symptoms, and number of visits with specific combinations of symptoms.
Results: On average, cases consulted more often than controls between birth and diagnosis/pseudodiagnosis with brain tumor signs and symptoms. Their consultation rate with >or=1 suggestive symptom escalated in the 2 years before diagnosis. Symptom prevalence was higher among cases than controls, a relative difference of 3.29 times as many consultations with >or=1 suggestive symptom (95% confidence interval [CI]: 2.82-3.83) and 7.01 as many with more than 1 (95% CI: 5.38-9.13). In each 6-month period in the 4 years before diagnosis, cases had at least twice as many consultations with >or=1 suggestive symptom (20.81 times as many in the 6 months before diagnosis [95% CI: 14.29-30.30]) and 2-3 times more records of suggestive symptoms (28.35 times more in the 6 months before diagnosis [95% CI: 19.05-42.19]). Symptoms rarely or not observed among control children included head tilt, odd head movements, odd posture, back or neck stiffness, and unsteadiness without obvious cause. CONCLUSION Key to identifying the 1 child among many who merits prompt investigation is recognition of unusual symptoms, or specific symptom patterns.
Virgilsen L, Vedsted P, Jensen H, Frederiksen H, El-Galaly T, Rasmussen L Eur J Haematol. 2024; 114(2):353-364.
PMID: 39533876 PMC: 11707810. DOI: 10.1111/ejh.14315.
McCarthy E, Marchese V, Shipper A, Rock K, Felter C Crit Rev Oncol Hematol. 2024; 201:104425.
PMID: 38909876 PMC: 11330360. DOI: 10.1016/j.critrevonc.2024.104425.
Tsze D, Kuppermann N, Casper T, Barney B, Richer L, Liberman D BMJ Open. 2023; 13(11):e079040.
PMID: 37993148 PMC: 10668138. DOI: 10.1136/bmjopen-2023-079040.
Delay in the diagnosis of paediatric brain tumours: a systematic review.
Kehoe K, Sivaguru H, Coulter I, Cowie C Childs Nerv Syst. 2023; 39(8):2053-2063.
PMID: 37336792 DOI: 10.1007/s00381-023-06022-y.
Adenosine Targeting as a New Strategy to Decrease Glioblastoma Aggressiveness.
Bova V, Filippone A, Casili G, Lanza M, Campolo M, Capra A Cancers (Basel). 2022; 14(16).
PMID: 36011024 PMC: 9406358. DOI: 10.3390/cancers14164032.